ProSpec-TNF a Mutant Human/CYT-384,Tumor Necrosis Factor-Alpha Mutant Human Recombinant

TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, Cachectin, DIF, TNFA, TNFSF2.

The clinical use of the potent anti-tumor activity of TNF-a has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-a, which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-? mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.
Recombinant Human TNF-a Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven tohave more activity and with less inflammatory side effect in vivo.

TNF-α 强效抗肿瘤活性的临床应用受到促炎副作用的限制，包括发热、剂量限制性低血压、肝毒性、血管内血栓形成和出血。设计具有低全身毒性的临床适用的 TNF-α 突变体一直是一个强烈的药理学兴趣。与小鼠 TNF-a 结合的小鼠 TNF-a 与小鼠 TNF-R55 结合但不与小鼠 TNF-R75 结合，在小鼠中表现出保留的抗肿瘤活性和降低的全身毒性，后者与两种小鼠 TNF 受体结合。基于这些结果，许多 TNF-?已经设计了选择性结合 TNF-R55 的突变体。这些突变体在体外对肿瘤细胞系表现出细胞毒活性，在体内表现出较低的全身毒性。
与野生型相比，重组人 TNF-a 变体/突变体具有来自 a.a. 的氨基酸序列缺失。 1-7，以及以下 a.a.替代 Arg8、Lys9、Arg10 和 Phe157，其在体内被证明具有更高的活性和更少的炎症副作用。

Tumor Necrosis Factor-a Variant Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16598 Dalton.
The TNF-alpha Variant is purified by standard chromatographic techniques.

Tumor Necrosis Factor-a Variant Human Recombinant 产生于 E.Coli 是一种单一的、非糖基化的多肽链，含有 151 个氨基酸，分子量为 16598 道尔顿。
TNF-α变体通过标准色谱技术纯化。

Escherichia Coli.

Sterile Filtered White lyophilized powder.

The protein was lyophilized after extensive dialysis against 0.5x PBS pH -7.

It is recommended to reconstitute the lyophilized Tumor Necrosis Factor-alpha Variant in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

建议在不低于 100µg/ml 的无菌 18MΩ-cm H2O 中重新配制冻干的肿瘤坏死因子-α 变异体，然后可以进一步稀释成其他水溶液。

Lyophilized Tumor Necrosis Factor-a Variant although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution TNF-a Variant should be stored at 4°C between 2-7 days and for future use below -18°C.
For long term storage it is recommended to add a carrier protein .
Please prevent freeze-thaw cycles.

冻干的肿瘤坏死因子-a 变体虽然在室温下可稳定保存 3 周，但应在 -18°C 以下干燥储存。 重组后 TNF-a 变体应在 4°C 下储存 2-7 天，以备将来在 -18°C 以下使用。
对于长期储存，建议添加载体蛋白。
请防止冻融循环。

Greater than 95.0% as determined by:
Analysis by RP-HPLC.
Analysis by -PAGE.

MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN
QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIAF.

The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is < 0.05ng/ml, corresponding to a Specific Activity of 20,000,000 units/mg.

Prospec’s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.